Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ixekizumab

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Lilly announces plans for $6bn US manufacture facility

    The site is the third of four new US sites that Lilly has announced

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    - PMLiVE

    Lilly announces plan for new $3bn facility to boost manufacturing in Europe

    The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

    - PMLiVE

    Lilly to invest $1.2bn in Puerto Rico manufacturing site

    The investment will strengthen Lilly’s US manufacturing network

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    - PMLiVE

    Novartis to acquire Avidity Biosciences in deal worth $12bn

    The acquisition will expand Novartis’ neuroscience pipeline

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links